Glassman Wealth Services’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q1 | – | Sell |
-152
| Closed | -$20K | – | 1218 |
|
|
2023
Q4 | $20K | Hold |
152
| – | – | ﹤0.01% | 688 |
|
|
2023
Q3 | $17.1K | Hold |
152
| – | – | ﹤0.01% | 697 |
|
|
2023
Q2 | $14.3K | Buy |
152
+6
| +4% | +$566 | ﹤0.01% | 713 |
|
|
2023
Q1 | $14.8K | Sell |
146
-4
| -3% | -$405 | ﹤0.01% | 708 |
|
|
2022
Q4 | $17.9K | Buy |
150
+4
| +3% | +$478 | ﹤0.01% | 689 |
|
|
2022
Q3 | $16K | Hold |
146
| – | – | ﹤0.01% | 678 |
|
|
2022
Q2 | $14K | Buy |
146
+139
| +1,986% | +$13.3K | ﹤0.01% | 723 |
|
|
2022
Q1 | $1K | Sell |
7
-119
| -94% | -$17K | ﹤0.01% | 1458 |
|
|
2021
Q4 | $11K | Sell |
126
-43
| -25% | -$3.75K | ﹤0.01% | 765 |
|
|
2021
Q3 | $16K | Buy |
169
+24
| +17% | +$2.27K | ﹤0.01% | 643 |
|
|
2021
Q2 | $14K | Hold |
145
| – | – | ﹤0.01% | 670 |
|
|
2021
Q1 | $14K | Buy |
145
+18
| +14% | +$1.74K | ﹤0.01% | 634 |
|
|
2020
Q4 | $12K | Buy |
127
+76
| +149% | +$7.18K | ﹤0.01% | 678 |
|
|
2020
Q3 | $5K | Buy |
51
+10
| +24% | +$980 | ﹤0.01% | 793 |
|
|
2020
Q2 | $5K | Buy |
41
+32
| +356% | +$3.9K | ﹤0.01% | 627 |
|
|
2020
Q1 | $1K | Buy |
9
+5
| +125% | +$556 | ﹤0.01% | 936 |
|
|
2019
Q4 | $0 | Sell |
4
-3
| -43% | – | ﹤0.01% | 1371 |
|
|
2019
Q3 | $1K | Buy |
7
+3
| +75% | +$429 | ﹤0.01% | 881 |
|
|
2019
Q2 | $0 | Buy |
+4
| New | – | ﹤0.01% | 1263 |
|